Innovations and Challenges in Renal Cancer
First Cambridge Conference
March 2004
Innovations and Challenges in Renal Cancer: Consensus Statement
Michael B. Atkins, David E. Avigan, Ronald M. Bukowski, Richard W. Childs, Janice P. Dutcher, Tim G. Eisen, Robert A. Figlin, James H. Finke, Robert C. Flanigan, Daniel J. George, S. Nahum Goldberg, Michael S. Gordon, Othon Iliopoulos, William G. Kaelin, Jr, W. Marston Linehan, Allan Lipton, Robert J. Motzer, Andrew C. Novick, Walter M. Stadler, Bin Tean Teh, James C. Yang, and Laura King
Genetic Basis of Cancer of the Kidney: Disease-Specific Approaches to Therapy
W. Marston Linehan, James Vasselli, Ramaprasad Srinivasan, McClellan M. Walther, Maria Merino, Peter Choyke, Cathy Vocke, Laura Schmidt, Jennifer S. Isaacs, Gladys Glenn, Jorge Toro, Berton Zbar, Donald Bottaro, and Len Neckers1
The von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer
William G. Kaelin, Jr.
Molecular Markers for Early Detection of Renal Carcinoma: Investigative Approach
Steven Skates and Othon Iliopoulos
Prognostic Factors for Survival of Patients With Stage IV Renal Cell Carcinoma: Memorial Sloan-Kettering Cancer Center Experience
Robert J. Motzer, Jennifer Bacik, and Madhu Mazumdar
Tissue Array-Based Predictions of Pathobiology, Prognosis, and Response to Treatment for Renal Cell Carcinoma Therapy
John S. Lam, Arie S. Belldegrun, and Robert A. Figlin
Prognostic Factors in Patients With Advanced Renal Cell Carcinoma: Development of an International Kidney Cancer Working Group
Ronald M. Bukowski, Sylvie Negrier, Paul Elson
Gene expression profiling of renal cell carcinoma
Min-Han Tan, Craig G. Rogers, Jeffrey T. Cooper, Jonathon A. Ditlev, Thomas J. Maatman, Ximing Yang, Kyle A. Furge, Bin Tean Teh
Laparoscopic and Partial Nephrectomy
Andrew C. Novick
Review of Radiofrequency Ablation for Renal Cell Carcinoma
Andrew Hines-Peralta, and S. Nahum Goldberg
Debulking Nephrectomy in Metastatic Renal Cancer
Robert C. Flanigan
Update on the Role of Interleukin 2 and Other Cytokines in the Treatment of Patients With Stage IV Renal Carcinoma
Michael B. Atkins, Meredith Regan, and David McDermott
Dendritic Cell-Tumor Fusion Vaccines for Renal Cell Carcinoma
David Avigan
Nonmyeloablative Transplantation: An Allogeneic-Based Immunotherapy for Renal Cell Carcinoma
Yoshiyuki Takahashi and Richard W. Childs
Effect of Renal Cell Carcinomas on the Development of Type 1 T-cell Responses
Patricia Rayman, Amy K Wesa, Amy L Richmond, Tanya Das, Kaushik Biswas,Gira Raval, Walter J. Storkus,Charles Tannenbaum, Andrew Novick, Ronald Bukowksi and James Finke
Bevacizumab for Patients With Metastatic Renal Cancer: An Update
James C. Yang
Tyrosine Kinase Inhibitors in Renal Cell Carcinoma
Anil Potti, Daniel J. George
Novel Antiangiogenic Therapies for Renal Cell Cancer
Michael S. Gordon
Mammalian Target of Rapamycin Inhibition
Janice P. Dutcher
Kinase Inhibition with BAY 43-9006 in Renal Cell Carcinoma
Tanya Ahmad and Tim Eisen
Therapeutic Options for Variant Renal Cancer: A True Orphan Disease
Walter M. Stadler
Skeletal Complications in Patients With Bone Metastases From Renal Cell Carcinoma and Therapeutic Benefits of Zoledronic Acid
Allan Lipton, Alejandro Colombo-Berra, Ronald M. Bukowski, Lee Rosen, Ming Zheng, Gladys Urbanowitz
